Theravance Biopharma (TBPH) Tops Q2 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Baird Cuts Price Target on Theravance Biopharma (TBPH) Following 2Q15
August 11, 2015 10:20 AM EDTBaird maintained a Neutral rating on Theravance Biopharma (NASDAQ: TBPH), and cut the price target to $14.00 (from $17.00), following its 2Q15 earnings results. TBPH recorded $7.1M in revenues for the quarter, ahead of consensus 4.25M. $(1.42) in EPS beat consensus estimates of $(1.51).
Analyst Brian Skorney... More
Theravance Biopharma (TBPH) Announces Receipt of FDA Fast-Track Designation for TD-8954 With Enteral Feeding in Critically Ill Patients
August 6, 2015 8:06 AM EDTTheravance Biopharma (NASDAQ: TBPH) announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to TD-8954 for short-term use with enteral feeding to achieve early nutritional adequacy in critically ill patients at high nutritional risk. TD-8954 is a selective 5-HT4 receptor agonist being evaluated for potential use in the treatment of gastrointestinal motility disorders, including enteral feeding intolerance (EFI). Importantly, there are currently no FDA-approved therapies for EFI, leaving the approximately one million Americans who suffer from the... More
